Earnings Call Summary | BAYER AG(BAYZF.US) Q1 2024 Earnings Conference
Earnings Call Summary | BAYER AG(BAYZF.US) Q1 2024 Earnings Conference
The following is a summary of the Bayer AG (BAYZF) Q1 2024 Earnings Call Transcript:
以下是拜耳公司（BAYZF）2024年第一季度财报电话会议记录摘要：
Financial Performance:
财务业绩：
Bayer reported Q1 sales of €13.8 billion, slightly lower than the previous year.
Core earnings per share stood at €2.82, also slightly below the previous year's earnings.
The company's free cash flow was negative €2.6 billion, which marked an improvement from Q1 of the preceding year, largely due to lower litigation payouts.
Crop Science unit sales were down by 3%, impacted by adverse weather conditions and lower glyphosate pricing, while the Pharmaceuticals business saw a 4% rise in sales largely due to strong performance from their new launched products.
拜耳报告称，第一季度销售额为138亿欧元，略低于上年。
每股核心收益为2.82欧元，也略低于上一年的收益。
该公司的自由现金流为负26亿欧元，与去年第一季度相比有所改善，这主要是由于诉讼支出减少。
受恶劣天气条件和草甘膦价格下跌的影响，作物科学部门的销售额下降了3％，而制药业务的销售额增长了4％，这主要是由于其新推出的产品的强劲表现。
Business Progress:
业务进展：
Both Pharmaceutical products, Nubeqa and Kerendia, are seeing growth.
Bayer introduced Iberogast to the US market after its success in Europe.
Significant reductions in management roles are expected to save approximately €500 million in 2024 and target savings of $2 billion by 2026.
As part of their Dynamic Shared Ownership, Bayer is consolidating roles and designing teams for greater impact.
Bayer's Pharmaceuticals team expects to have readouts of Kerendia's first Phase 3 study in heart failure and Nubeqa's ARANOTE trial.
Despite competition, Eylea is showing positive longevity and volume increases in most territories.
Their Consumer Health segment has globally initiated around 90 teams, with one team reducing the product launch time from 36 months to 9 months in the ASEAN region.
Bayer is also working towards improving its supply situation for better product availability and gaining market share in key products.
Nubeqa和Kerendia这两种制药产品都在增长。
拜耳在欧洲取得成功后，将Iberogast引入了美国市场。
预计在2024年大幅裁减管理职位将节省约5亿欧元，目标是到2026年节省20亿美元。
作为其动态共享所有权的一部分，拜耳正在整合角色和设计团队，以提高影响力。
拜耳制药团队预计将公布克伦迪亚首项心力衰竭三期研究和努贝卡的ARANOTE试验。
尽管存在竞争，但Eylea在大多数地区的使用寿命和销量都呈现出积极的增长态势。
他们的消费者健康部门已在全球组建了约90个小组，其中一个团队将东盟地区的产品发布时间从36个月缩短到9个月。
拜耳还努力改善其供应状况，以提高产品可用性并获得关键产品的市场份额。
More details: BAYER AG IR
更多详情： 拜耳股份公司
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多详情，请访问投资者关系网站。本文仅供投资者参考，不构成任何投资建议。
译文内容由第三方软件翻译。